Financials

	2025 *	2026 *
Net sales	296M 255M 237M 221M 412M 26.75B 444M 2.73B 1.07B 12.79B 1.11B 1.09B 47.15B	403M 347M 323M 300M 560M 36.43B 604M 3.72B 1.46B 17.41B 1.51B 1.48B 64.21B
Net income	3.48M 2.99M 2.79M 2.59M 4.83M 314M 5.21M 32.06M 12.6M 150M 13.05M 12.78M 554M	13.34M 11.46M 10.69M 9.93M 18.53M 1.2B 19.99M 123M 48.29M 576M 50.03M 49M 2.12B
Net Debt	-445M -382M -357M -331M -618M -40.19B -667M -4.1B -1.61B -19.21B -1.67B -1.63B -70.83B	-478M -411M -383M -356M -664M -43.17B -716M -4.4B -1.73B -20.63B -1.79B -1.76B -76.09B

More financial data * Estimated data

Company Profile

Employees

620

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-01-13	98.02 $	-1.14%	80,950
26-01-12	99.15 $	+15.37%	277,907
26-01-09	85.94 $	-1.88%	198,131
26-01-08	87.59 $	-2.07%	160,975
26-01-07	89.44 $	-5.73%	208,903

Delayed Quote Nasdaq, January 13, 2026 at 02:23 pm EST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

99.15USD

Average target price

135.29USD

Spread / Average Target

+36.45%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 02:38:54 2026-01-13 pm EST			5-day change	1st Jan Change
99.06 ^USD	-0.09%		+2.91%	+19.31%

Jan. 12	BillionToOne Reaffirms 2025 Revenue Guidance, Issues 2026 Guidance	MT
Jan. 12	(BLLN) BillionToOne Expects 2025 Revenue Range $293M - $299M, vs. FactSet Est of $296.2M	MT

Capitalization	4.54B 3.9B 3.64B 3.38B 6.3B 410B 6.8B 41.81B 16.43B 196B 17.02B 16.67B 722B	P/E ratio 2025 *	936x	P/E ratio 2026 *	447x
Enterprise value	4.09B 3.52B 3.28B 3.05B 5.69B 370B 6.13B 37.71B 14.82B 177B 15.35B 15.03B 651B	EV / Sales 2025 *	13.8x	EV / Sales 2026 *	10.1x
Free-Float	-	Yield 2025 *	-	Yield 2026 *	-

Jan. 12	BillionToOne Reaffirms 2025 Revenue Guidance, Issues 2026 Guidance	MT
Jan. 12	(BLLN) BillionToOne Expects 2025 Revenue Range $293M - $299M, vs. FactSet Est of $296.2M	MT
Jan. 12	(BLLN) BillionToOne Expects 2026 Total Revenue Range $415M to $430M, vs. FactSet Est of $402.3M	MT
Jan. 12	Billiontoone provides guidance for 2026	RE
Jan. 12	Billiontoone, Inc. Provides Earnings Guidance for 2026	CI
Jan. 06	BillionToOne, Inc. Announces Selection of Northstar Select as New Liquid Biopsy Test for LC-SCRUM-TRY Clinical Study at National Cancer Center Hospital East	CI
Jan. 06	Billiontoone announces selection of Northstar Select® as the new liquid biopsy test	RE
Jan. 06	Guggenheim Initiates BillionToOne at Buy With $120 Price Target	MT
Dec. 21	BillionToOne, Inc.(NasdaqGS:BLLN) added to S&P TMI Index	CI
Dec. 12	BillionToOne, Inc., Q3 2025 Earnings Call, Dec 09, 2025
Dec. 09	BillionToOne Q3 Swings to Profit, Revenue Rises; Shares Fall After Hours	MT
Dec. 09	(BLLN) BillionToOne Expects Full Year 2025 Revenue Range $293M - $299M, vs. FactSet Est of $288.6M	MT
Dec. 09	Earnings Flash (BLLN) BillionToOne Posts Q3 EPS $0.10, vs. FactSet Est of $0.14	MT

Jan. 06	Guggenheim Initiates BillionToOne at Buy With $120 Price Target	MT
Dec. 09	(BLLN) BillionToOne Expects Full Year 2025 Revenue Range $293M - $299M, vs. FactSet Est of $288.6M	MT
Dec. 01	BillionToOne Shares Fall After Jefferies Initiates Coverage at Hold	MT
Dec. 01	Jefferies Initiates BillionToOne at Hold With $117 Price Target	MT
Dec. 01	Stifel Initiates BillionToOne at Buy With $145 Price Target	MT

BillionToOne, Inc. Stock

Equities

BLLN

US0901681058

Biotechnology & Medical Research

Valuation: BillionToOne, Inc.

Chart: BillionToOne, Inc.

Latest news: BillionToOne, Inc.

Last Transcript: BillionToOne, Inc.

Analysts' recommendations: BillionToOne, Inc.

Press Releases: BillionToOne, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: BillionToOne, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Jan. 12	BillionToOne Provides Guidance for 2026	GL
Dec. 23	BillionToOne to Participate in the 44th Annual J.P. Morgan Healthcare Conference	GL
Dec. 09	BillionToOne Reports Third Quarter 2025 Results	GL
Dec. 02	BillionToOne to Report Third Quarter 2025 Financial Results on December 9, 2025	GL
Nov. 07	BillionToOne Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	AQ

1 day	-0.09%
1 week	+2.91%
Current month	+19.31%
1 month	+1.04%
Current year	+19.31%

1 week	83.3	101.98
1 month	80.51	105.89
Current year	83	101.98
1 year	80.51	138.7
3 years	80.51	138.7
5 years	80.51	138.7
10 years	80.51	138.7

Manager	Title	Age	Since
David Tsao PSD	President	37	2015-12-31
Atay Oguzhan CEO	Chief Executive Officer	38	2015-12-31
Ross Taylor DFI	Director of Finance/CFO	62	2023-12-31

Director	Title	Age	Since
Kittu Kolluri BRD	Director/Board Member	62	2019-02-28
Thomas S. Bremner BRD	Director/Board Member	44	2022-02-28
Akshay Rai BRD	Director/Board Member	42	2024-04-30

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
BILLIONTOONE, INC.	-0.09%	+2.91%	-	-	4.54B
LONZA GROUP AG	-0.92%	+4.67%	+2.98%	+14.95%	49.9B
IQVIA HOLDINGS INC.	+0.04%	+0.24%	+17.82%	+8.54%	41.02B
BEONE MEDICINES AG	+3.50%	+8.51%	+88.29%	+28.43%	36.96B
CELLTRION, INC.	+1.88%	+7.16%	+21.92%	+42.32%	31.91B
REVOLUTION MEDICINES, INC.	+0.93%	+49.00%	+179.48%	+295.40%	22.65B
REGENCELL BIOSCIENCE HOLDINGS LIMITED	-23.38%	+1.45%	+24,870.19%	+4,160.11%	21.81B
MEDPACE HOLDINGS, INC.	+1.05%	-0.65%	+71.85%	+164.66%	16.88B
EUROFINS SCIENTIFIC SE	+1.98%	+8.91%	+49.19%	+13.12%	14.8B
ICON PUBLIC LIMITED COMPANY	+1.41%	-9.47%	-16.33%	-18.75%	13.76B
Average	-1.26%	+13.33%	+2,809.49%	+523.20%	25.42B
Weighted average by Cap.	-0.93%	+12.58%	+2,215.16%	+415.10%